Dr Md Ezharul Hoque Chowdhury
Jeffrey Cheah School of Medicine & Health Sciences
Tel: +603 5515 9660
Office: Room 4-4-25
Dr Md Ezharul Hoque Chowdhury completed his Doctor of Engineering at Tokyo Institute of Technology in 2003 under the supervision of Professor Toshihiro Akaike. Subsequently, he worked there as a research fellow and a team leader till the end of 2006 before joining as a tenure-track assistant professor at the same Institute and a visiting assistant professor at Shizuoka Cancer Center Institute. In 2011, he joined Monash University Malaysia as a senior lecturer and promoted to associate professor in 2013.
Dr Ezharul has created a new branch in nanomedicine delivery by developing for the first time pH-sensitive inorganic nanoparticles with fascinating properties which confer notable advantages over the conventional carriers. This is indeed a substantial advancement in the field, considering the limitations of the existing nano-carriers, such as instability in plasma, insufficient release of drugs from the carriers and unwanted side- effects (toxicity). Despite tremendous efforts and heavy investment in the last four decades, due to the lack of an ideal delivery system with appropriate features to overcome those barriers, the world could not see the notable success of this particular field in clinical trials. Based on the highly promising pre-clinical data obtained in animal models with the smart nano-devices in delivering small molecule anti-cancer drugs, functional genes and selective siRNAs, Dr Ezharul is quite optimistic to see the actual success in clinical trials with his nano-formulations which showed impressive therapeutic efficacy with a drug dose almost 100-fold lower than that traditionally used. The rapid biodegradability of these mineral nanoparticles along with the requirement of pretty low amount of the drugs resulted in no adverse effects usually noticed with traditional nano-formulations. It should be noteworthy that his team has elucidated the mechanism of intracellular delivery of drugs using these particles, and additionally, cellular processing of the particle constituents released after particle dissolution. Additionally, the team has established the technology in delicately controlling the particle diameter for ensuring favourable pharmacokinetics as well as passive targeting of the nanoparticles to selective tissues having leaky vasculature. In order for receptor-mediated (active) targeting, multiple strategies have been designed for surface functionalization of nanoparticles based on electrostatic interactions between the nanoparticles and specific ligands.
So far, Dr Ezharul has achieved 25 research grants as principle investigator (PI) and is currently involved in supervising 10 PhD students. He has published more than 100 original articles in internationally reputed journals in addition to one complete written book. He is one of the inventors of seven US, Japanese and Malaysian patents some of which are already in the pipeline for being commercialized. His research profile can be found in the following websites:
2012-2014: Graduate Certificate in Higher Education, Monash University, Australia
2000-2003: Doctor of Engineering in Biomolecular Engineering, Tokyo Institute of Technology, Tokyo
1998-2000: Master of Science in Biochemistry, University of Dhaka, Dhaka, Bangladesh
1993-1998: Bachelor of Science in Biochemistry, University of Dhaka, Dhaka, Bangladesh
2011- 2013: Senior Lecturer, Monash University (Sunway Campus)
2008- 2011: Senior Lecturer, International Medical University
2006- 2008: Assistant Professor (Independent), Tokyo Institute of Technology
2006- 2008: Visiting Professor & Lab Chief, Shizuoka Cancer Center Research Institute
2006- 2006: Researcher & Group Leader, Tokyo Institute of Technology
2006- 2006: Visiting Researcher & Lab Chief, Shizuoka Cancer Center Research Institute
2004- 2006: Research Fellow of JSPS, Tokyo Institute of Technology
2003- 2004: Post-doctoral Researcher, Tokyo Institute of Technology
Research & Education
In the past four decades, the world witnessed the discovery of liposomes, solid lipid nanoparticles, polymeric nanoparticle and other non-biodegradable nanoparticles as carriers of traditional small molecule drugs and new generation marcromolecular drugs (genes, siRNAs, proteins) to enhance the therapeutic efficacy and reduce the side effects; however, limited successes were noticed so far with regards to the eventual clinical benefits utilizing the existing technology. During the thirteen years of Dr Ezharul’s independent research career, he has fully concentrated to establish a team so as to address the critical issues involved in delivery of the small and large molecule drugs. Although it was so exciting initially to contribute to the field, challenges were subsequently embraced in securing the competitive funding to support his research assistants and post-doctoral fellows as well as to bear the cost of consumable research items and equipment. The pressure for publications was another big challenge particularly for a researcher like Dr Ezharul who intended to focus on a very specific area with much uncertainty of having positive outcomes. Originally driven by an accidental finding while working at Tokyo Institute of technology, he has been able to create a new branch in nanomedicine delivery by developing for the first time pH-sensitive inorganic nanoparticles with fascinating and unique properties which confer notable advantages over the conventional carriers, such as strong electrostatic affinity towards the small and macromolecular drugs, excellent bio-distribution profile and tissue- targetability after intravenous administration of surface-modified, drug-loaded complexes and finally, pH-responsive dissolution of the particles with consequential release of the drugs in the acidic compartments (endosomes), following internalization by the target cells. This is indeed a substantial advancement in the field, considering the limitations of the existing nano-carriers, such as instability in plasma, insufficient release of drugs from the carriers and unwanted side- effects (toxicity).
With a view to translate the research findings into beneficial products for humans, Dr Ezharul and his team are currently focusing on tailoring of their nanotechnology for treatment of cancers, particularly breast carcinoma. They have undertaken a number of strategic projects to predominantly target their nano-carriers to the cancer cells by overcoming the multiple barriers commonly faced after systemic delivery, while discovering alongside novel potential key cellular targets responsible for cancer cell progression and survival.
Dr Md Ezharul Hoque Chowdhury has been teaching for the last 8 years since 2004
Taught courses in Tokyo Institute of Technology, 2004 – 2008 :
- Biomedical Engineering
- Tissue Engineering
- Drug delivery
- Molecular diagnosis
- Cell signaling
Taught courses in International Medical University (IMU) and Monash University Malaysia, 2008 - Present:
- Cell and molecular biology
- Toxicology and toxinology
- Practice-based learning (PBL) for the following modules:
- Respiratory system
- Cardiovascular system
- Gastrointestinal system
- DNA finger printing
- Coordination of ‘Master of Biomedical Science’ program
- Involvement in accreditation of current and new programs
- Coordination of courses at Tokyo Tech and International Medical University
Chowdhury, E. H. Nanotherapeutics: From Laboratory to Clinic. CRC Press, 2016 (In press). The most comprehensive, harmonious, illustrative, and up-to-date book on nanotherapeutics or nanomedicine. Link: https://www.crcpress.com/Nanotherapeutics-From-Laboratory-to-Clinic/Chowdhury/9781498707510
Original Research Papers (Selected)
Tiash S, Kamaruzman NIB, Chowdhury EH. Carbonate apatite nanoparticles carry siRNA(s) targeting growth factor receptor genes egfr1 and erbb2 to regress mouse breast tumor. Drug Deliv. 2018 Nov;24(1):1721-1730 (Impact factor 6.4).
Mehbuba Hossain S, Chowdhury EH. Citrate- and Succinate-Modified Carbonate Apatite Nanoparticles with Loaded Doxorubicin Exhibit Potent Anticancer Activity against Breast Cancer Cells. Pharmaceutics. 2018 Mar 11;10(1). (Impact factor 3.83)
Fatemian T, Chowdhury EH. Cytotoxicity Enhancement in Breast Cancer Cells with Carbonate Apatite-Facilitated Intracellular Delivery of Anti-Cancer Drugs. Toxics. 2018 Feb 5;6(1).
Sheikh Tanzina Haque and Ezharul Hoque Chowdhury. Recent Progress in Delivery of Therapeutic and Imaging Agents Utilizing Organic-Inorganic Hybrid Nanoparticles. Current Drug Delivery, 2017. (Impact factor 2.25)
Fitya Syarifa Mozar and Ezharul Hoque Chowdhury. Impact of PEGylated Nanoparticles on Tumor Targeted Drug Delivery. Current Pharmaceutical Design,2018. (Impact factor 3.45)
Fitya Syarifa Mozar and EzharulHoque Chowdhury. PEGylation of carbonate apatite nanoparticles prevents opsonin binding and enhances tumor accumulation of gemcitabine. Journal of Pharmaceutical Sciences, 2018 (Impact factor 2.7)
Md. Emranul Karim, Kyi Kyi Tha, Iekhsan Othman, Mohammad Borhan Uddin & Ezharul Hoque Chowdhury. Therapeutic potency of nanoformulations of siRNAs and shRNAs in animal models of cancers. Pharmaceutics. 2018 (Impact factor 3.83)
Mozar FS, Chowdhury EH. Surface-Modification of Carbonate Apatite Nanoparticles Enhances Delivery and Cytotoxicity of Gemcitabine and Anastrozole in Breast Cancer Cells. Pharmaceutics. 2017 Jun 7;9(2) (Impact factor 3.83).
Tiash S,, ChowdhuryEH. Knockdown of ROS1 gene sensitizes breast tumor growth to doxorubicin in a syngeneic mouse model. Int J Oncol. 2016 (In Press) (Impact factor 3.03).
Tiash S, Chowdhury EH. Passive targeting of cyclophosphamide-loaded carbonate apatite nanoparticles to liver impedes breast tumor growth in a syngeneic model. Curr Pharm Design. 2016 (In press) (Impact factor 3.45).
Mozar FS, Chowdhury EH. Gemcitabine interacts with carbonate apatite with concomitant reduction in particle diameter and enhancement of cytotoxicity in breast cancer cells. Curr Drug Deliv. 2015;12(3):333-41 (Impact factor 2.25).
Ahmad A, Othman I, Md Zain AZ, Chowdhury EH. Controlled release of insulin in blood from strontium-substituted carbonate apatite complexes. Curr Drug Deliv. 2015;12(2):210-22 (Impact factor 2.25).
Kunnath, A.P., Tiash, S., Fatemian, T., Morshed, M., Shar, S.M., Chowdhury, E. H. Intracellular delivery of ERBB2 siRNA and p53 gene synergistically inhibits the growth of established tumor in an immunocompetent mouse. J Cancer Sci Ther , 2014: 6: 099-104. (Impact factor 5.8).
Yusuf, S., Chowdhury, E. H., Rosli, R., Hassan, F and Abdullah, S. Gene delivery potential of bio functional carbonate apatite nanoparticles in lungs. BioMed Research International, 2014;2014:646787. (Impact factor 2.88).
Tiash, S., Othman, I., Rosli. R., Chowdhury, E.H. Methotrexate- and cyclophosphamide-embedded pure and strontiumsubstituted carbonate apatite nanoparticles for augmentation of chemotherapeutic activities in breast cancer cells. Curr Drug Deliv. 2014, 2014;11(2):214-22 (Impact factor 2.25).
Kunnath AP, Kamaruzman NI, Chowdhury EH. Nanoparticle-facilitated Intratumoral Delivery of Bcl-2/IGF-1R siRNAs and p53 Gene Synergistically Inhibits Tumor Growth in Immunocompetent Mice. Journal of Nanomedicine and Nanotechnology, 2014, 6(2), 1-9 (Impact factor 5.72).
Hossain, S., Yamamoto, H., Chowdhury, E. H., et al. Fabrication and intracellular delivery of doxorubicin/carbonate apatite nanocomposites: Effect on growth retardation of established colon tumor. PLoS One. 2013, 16; 8(4):e60428. (Impact factor 4.092).
Hossain S, Sultana N, Chowdhury EH. PKC Activation Promotes Internalization of DNA-Immobilized Inorganic Nano-Crystals by Clathrin-Dependent Endocytosis for Efficient Transgene Expression in Human Lymphocytes. J Nanomed Nanotechol, 2013, 4:174. (Impact factor 5.72).
Chua MJ, Snigdha Tiash, Fatemian T, Noordin MI, Keng CS & Chowdhury EH. Carbonate apatite-facilitated intracellular delivery of c-ROS1 siRNA sensitizes MCF-7 breast cancer cells to cisplatin and paclitaxel. OA Cancer, 2013 Jun 19;1(1):7. (Impact factor has yest to released).
Review Papers (selected)
Ashaie, M. A. & Chowdhury, E. H. Cadherins: the superfamily critically involved in breast cancer. Current Pharmaceutical Design, 2015 (In press) (Impact factor 3.45).
Bakhtiar, A., Sayyad, M., Rosli, R., Maruyama, A. & Chowdhury, E. H. Intracellular delivery of potential therapeutic genes: Prospects in cancer gene therapy. Current Gene Therapy. 2014;14(4):247-57. (Impact factor 5.3).
Fatemian T, Chowdhury EH. Targeting oncogenes and tumor suppressors genes to mitigate chemoresistance. Curr Cancer Drug Targets. 2014;14(7):599-609 (Impact factor 3.58).
Fatemian, T, Othman, I & Chowdhury, E. H. Strategies and validation for siRNA-based therapeutics for reversal of multi-drug resistance in cancer, Drug Discovery Today, 2014 19(1):71-8 (Impact factor 6.5).
Chowdhury, E. H. pH-sensitive nanocrystals of carbonate apatite- a powerful and versatile tool for efficient delivery of genetic materials to mammalian cells, “Advances in Biomaterials Science and Applications in Biomedicine”. Eds., Pignatello R, InTech, Croatia, 2013.
Hossain, S, Chowdhury, E. H. and Akaike, T. Inorganic nanomaterials of carbonate apatite as intracellular nucleic acid/drug transporters,” Bioengineered Nanomaterials’, Eds., Atul Tiwari; Ashutosh Tiwari, Linköping University, Sweden, 2013, 149–162.
E. H. Chowdhury. Patent title: Bio-responsive nano-materials for efficient therapeutic transport. Malaysian Patent Application No. PI2014702983. Filing Date: 10/10/2014.
E. H. Chowdhury and T. Akaike. Patent title: Purification of plasmid DNA. Japanese Patent Application No. 2005-192605. Filing Date: 30/06/2005.
E. H. Chowdhury and T. Akaike. Patent title: Plasmid DNA delivery through integrin. Japanese Patent Application No. 2005-232504. Filing Date: 10/08/2005.
E. H. Chowdhury and T. Akaike. Patent title: Mg2+-inspired nano-apatite generation for high efficiency gene delivery into mammalian cells. Provisional US Patent Application No. 60/532,845. Filing Date: 12/26/2003. PCT Application No. PCT/JP2004/019549. Filing Date: 27/12/2004.
E. H. Chowdhury, F.T. Zohra and T. Akaike. Patent title: mRNA delivery with apatites. Japanese Patent Application No. 2005-252057. Filing Date: 31/08/2005.
E. H. Chowdhury, A. Maruyama and T. Akaike. Patent title: Gene-delivery Method. Provisional US Patent Application No. 60/425,291. Filing Date: 11/12/2002. PCT Application No. PCT/JP03/14376. Filing Date: 12/11/2003. PCT Publication Date: 27/05/2004; Patent No. WO 2004/043495. Japanese Patent Publication Date: 23/03/2006; Patent No. 2006-509838.
Competitive Research Grants as Principal Investigator (PI)
2004-2006: Super-efficient DNA/RNA Delivery for Cell-specific Therapy Based on Carbonate Apatite Nano-particles (Japan Society for the Promotion of Science) (JPY: 1,500,000).
2006-2008: Cancer therapy through cell-specific delivery of genes and gene-silencing components by using multifunctional, pH-sensitive inorganic nano-particles (Japan Science and Technology Corporation) (JPY: 22,000,000).
2008-2009: Gene Delivery to Leukemia Cells using Bio-Functional Carbonate Apatite Nano-Particles (IMU 172/08) (RM 20,000).
2009-2010: Gene silencing for inhibition of cancer cell proliferation and survival: A new strategy for cancer therapy (BMS I01-2009(06)) (RM 20,000).
2009-2009: Delivery of anti-cancer drugs to breast cancer cells using nano-particles (Bpharm B0106_Res1912009) (RM 5,000).
2009-2009: Efficient isolation of high quality Plasmid DNA from bacteria (Bpharm B0106_Res182009) (RM 10,000).
2010-2010: Nanoparticle-mediated Delivery of Small Interfering RNAs (siRNAs) Against "Cell Adhesion receptor" Genes for Tumor Cell Killing in Presence of Absence of Anti-Cancer Drugs (BPharm B0107_Res(16)2010) (RM 10,000).
2010-2010: Silencing of ABC Transporter Genes with Nanoparticle-mediated Delivery of Small Interfering RNAs (siRNAs) for induction of Apoptosis in cancer Cells (BPharm B0107_Res(17)2010) (RM 5,000).
2011-2011: Intracellular Proteinase delivery using pH-sensitive Nanoparticles for anti-Tumor Activity. (MB I 01/2008(01)2010) (RM 10,000).
2011-2011: Silencing of Tyrosine Kinase Gene Expression for Inhibition of Cancer Cell Proliferation and Survival (MB I01/2008(02)2010) (RM 10,000).
2009-2011: Targeted delivery of anti-cancer drugs to breast cancer cells using bio-functional carbonate apatite nano-particles (E-Science Project ID 02-02-09-SF0013) (RM 205,000).
2011-2011: Oral delivery of insulin embedded with carbonate apatite nano-particles: Protection against enzymatic degradation, transcellular and controlled release in blood. (Project code: M-CAR-RS (RM 20,000).
2010-2012: Inhibition of cancer cell proliferation and survival through synergistic effects of traditional anti Cancer drug action in combination with targeted knockdown of cancer-related genes (IMU 219/2010) (RM 40,000).
2012-2012: Super-sensitive biosensor development based on monoclonal antibody-immobilized nanoparticles for early detection of dengue virus (Budget code: 5140028 (RM 30,000).
2013-2013: Investigating the effects of physico-chemical and biological parameters affecting quality of Halal Meat (RM 20,000).
2010-2013: Induction of Apoptosis in Breast Cancer Cells through Combined Intracellular Delivery of a Tumor suppressor Gene and Small interfering RNAs Against Growth Factor Receptor and anti-apoptotic Genes (IMU 220/2010) (RM 60,000).
2013-2014: Development of bio-responsive inorganic nano-crystals and implementation in conventional drug delivery, gene therapy and tissue engineering. Seed grant from Advanced Engineering Platform (AEP), Monash University (Sunway Campus) (RM 54,000)
2012-2014: Targeted delivery of small interfering RNAs (siRNAs) against oncogenes using pH-sensitive nanoparticles for inhibition of cancer cell proliferation and survival (E-Science Project ID Project ID: 02-02-10-SF0083) (RM 296,000).
2013-2014: Breast cancer-targeted delivery of anti-cancer drugs using pH-sensitive inorganic nanoparticles, JCSMH grant for supporting MBioMedSc research project (RM 10,000).
2014-2014: Anti-cancer drug transport to breast cancer cells using mineral nanoparticles, JCSMH grant for supporting BMedSc research project (RM 10,000).
2014-2014: Intracellular delivery of small interfering RNAs (siRNAs) for inhibition of proliferation/survival and augmentation of chemotherapeutic effects in breast cancer cells, JCSMH grant for supporting BMedSc research project (RM 10,000).
2014-2015: Investigation of Breast Cancer Growth and Metastasis Inhibition in Response to Overexpression of P53 Gene and Targeted Knockdown of Growth Factor Receptor and Anti-Apoptotic Genes (FRGS, MOHE) (RM 125,000).
2015-2017: Multi-functionalcancer nano-therapeuticsdeliveringa cocktail of classical drugs, tumor suppressor genes and anti-sense RNAsto blockmulti-drug resistance and cancer progression (E-Science Project ID Project ID: 02-02-10-SF0299) (RM 198,000).
Supervisions at Monash University Malaysia
Ms. Snigdha Tiash, Title: Apoptosis induction in cancer cells with nanoparticle-facilitated delivery of classical anti-cancer drugs and siRNAs targeting growth factor receptor and multi-drug transporter genes (completed, currently working as a post-doct at University of Melbourne, Australia)
Ms. Tahereh Fatemian, Title: Intracellular delivery of p53, oncogenic siRNAs and anti-cancer drugs using pH-sensitive inorganic nanoparticles for induction of apoptosis in breast cancer cells
Ms. Nur Izyani Kamaruzman, Title: Targeted delivery of small interfering RNAs (siRNAs) against oncogenes using pH-sensitive nanoparticles for inhibition of cancer cell proliferation and survival
Ms. Athirah Bakhtair, Title: Development of novel inorganic nano-crystals for delivery of plasmid DNA and siRNA to mammalian cells
Mr. Anil Philips Kunath, Title: Induction of Apoptosis in Breast Cancer Cells through Combined Intracellular Delivery of a Tumor suppressor Gene and Small interfering RNAs Against Growth Factor Receptor and anti-apoptotic Genes
Mr Syafiq Asnawi Zainal Abidin. Disintegrins and cytotoxins from Malaysian Vipers and their mechanisms of action on human colorectal cancer cells
Ms. Nabilah Baby. Breast cancer-targeted delivery of tumor suppressor genes, oncogene-specific siRNAs and classical anti-cancer drugs using monoclonal antibody-coated inorganic nanoparticles
Ms. Jayalaxmi Shetty. Development of bio-functional inorganic nanoparticles for efficient delivery of siRNA, therapeutic gene and anti-cancer drugs to breast cancer cells
Rahela Zaman. Fabrication of Oral Nano-Insulin Formulation for Regulating Blood Glucose Level
Ahsanul Kaiser. Laser-responsive drug delivery and imaging to targeted cancer cells based on carbonate apatite nanoparticles
Maeirah Ashaie, Perturbation of cell-cell and cell-macromolecule interactions and their associated signalling cascades by biodegradable nanoparticle-assisted delivery of siRNA and study of consequential chemosensitization of breast cancer
Mr. Suleiman Haji, Title: Intranasal delivery of plasmid DNA using carbonate apatite nanoparticles (completed).
Chua Ming Jang. Inhibition of cancer cell proliferation and survival through synergistic effects of traditional anti-cancer drug action in combination with targeted knockdown of cancer-related genes
Ms. Fitya Syarifa, Title: Breast cancer-targeted delivery of anti-cancer drugs using pH-sensitive inorganic nanoparticles.
Mr. Aiman Ahmad, Title: Controlled release of insulin from insulin-apatite nano-composites for the treatment of diabetes (completed, currently working in Qatar as a medical doctor)
Mr. Mohammad Fahad Sorefan, Title: Intracellular delivery of small interfering RNAs (SiRNAs) for inhibition of proliferation/survival and augmentation of chemotherapeutic effects in breast cancer cells (completed, currently working in Australia as a medical doctor)
Ms. Chong Chia Yuen, Title: Anti-Cancer drug transport to breast cancer cells using mineral nanoparticles (completed, currently working in Australia as a medical doctor)
Supervisions at Tokyo Tech
K. Kutsuzawa ‘Extracellular matrix (ECM) protein-coated carbonate apatite particles for gene delivery to mouse embryonic stem cells’ (completed, currently working as a post-doct, Tokyo Institute of Technology, Japan)
‘Apatite-liposome hybrid carrier for efficient mRNA delivery’ (completed, currently working as a post-doctoral, Drexel University College of Medicine, USA)
‘Design of carbonate apatite nano-carrier for siRNA and anti-cancer drug delivery’ (completed, currently working as an Assistant Professor, Jahangirnagar University, Dhaka, Bangladesh)
Dr Md. Ezharul Hoque Chowdhury has supervised one master student as a co- supervisor at Tokyo tech with the title ‘Development of an anti-cancer drug delivery system based on carbonate apatite nanoparticles’ (completed)
Dr Md. Ezharul Hoque Chowdhury has also supervised an undergraduate student as the main supervisor on the topic of ‘leukemic cell transfection by carbonate apatite nanoparticles’ (completed)
Student Supervisions at International Medical University (IMU)
Ms. Ming Jang Chua, Title: Inhibition of Cancer Cell Proliferation and Survival Through Synergistic Effects of Traditional Anti Cancer Drug Action in Combination with Targeted Knockdown of Cancer-related Genes (completed, currently working as a doctoral student, Griffith University, Brisbane, Australia)
Undergraduate students (completed)
1 BMed Science student
7 Pharmacy students
4 Medical Biotechnology students at IMU
- 2000-2003: Monbusho (Ministry of Education, Science, Sports and Culture) Scholarship, the most honorable scholarship in Japan
- 2004-2006: JSPS Fellowship, the most prestigious post-doctoral fellowship in Japan
- Outstanding oral presentation award at ICBME held in Singapore (2005)
- Tejima Memorial Prize of Japan (2007)
- Monash Pro-Vice Chancellor (PVC) Award for Excellence in Research (2011)
- Monash Pro-Vice Chancellor (PVC) Award for Excellence in Research (2012)
- Monash Pro-Vice Chancellor (PVC) Award for Excellence in Research (2013)
- Gold Medal in 27th International Invention & Innovation Exhibition (ITEX) (2016)
- The impact of nanotherapeutics in transforming the medicine. International Conference on Medical Science Technology (ICMST). 23-24 November 2016, Grand ballroom Hotel Bangi Putrajaya (Plenary speech)
- pH-sensitive inorganic nano-crystals for smart and targeted delivery of anti-cancer drugs and small interfering RNA (siRNA). International Research Symposium on Engineering and Technology (IRSET). 13-15 September, 2016, M Hotel Singapore (Keynote speech).
- pH-sensitive inorganic nanoparticles for efficient delivery of anticancer drugs to breast cancer cells. 2nd International Conference on Innovations in Engineering and Technology (ICCET’2014). Sep 19-20, 2014, Bayview Hotel Georgetown, Penang.
- Nanomedicine delivery with bio-functional inorganic nano-particles. International Meeting on New Trends in Biotechnology. Monash University Malaysia, Dec 12-13, 2013.
- Targeted gene knockdown for reversal of multi-drug resistance in cancer. Bio-IT World Asia Conference. Marina Bay Sands, Singapore, May 28-31, 2013.
Editing and Reviewing Journal Papers
Dr Md Ezharul Hoque Chowdhury is one of the editorial board members for International Journal of Nanomedicine, Drugs and Therapy Studies, OA cancer, Journal of Cancer Metastasis and Treatment and Journal Recent Patents on Drug Delivery & Formulation.
He is also the editor of submitted research papers for the conference proceedings in Tsinghua - Tokyo Tech & Shizuoka Cancer Center Triangle Symposium on Cancer Biology & Bioengineering” 2006, Oct 27, 2006, Shizuoka, Japan and The 1st International Symposium on Cancer Therapy and Regenerative Medicine, Oct 6, 2007, Shizuoka, Japan.